Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · February 24, 2024

Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab for Pretreated Gastric Cancer

Clinical Cancer Research

 

 Save  Recommend
 Share

Additional Info

Clinical Cancer Research
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Clin. Cancer Res 2024 Jan 31;[EPub Ahead of Print], A Kawazoe, N Yamamoto, N Sugimoto, H Kawakami, T Oshima, K Yamaguchi, K Hino, M Hirao, Y Kurokawa, T Kawakami, M Tsuda, H Hara, S Kaname, D Matsuoka, Y Otake, K Yasuda, T Takase, S Takashima, T Semba, K Muro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated